Q Therapeutics
Dr. Campanelli serves as Vice President of Research and Development at Q Therapeutics.
At Q Therapeutics, since 2004, he has led all R&D and IND enabling activities related to the Company’s proprietary, patented Q-Cells® technology, including the successful submission of Q’s first IND for the ALS indication. He also manages interactions with external collaborators working to develop Q-Cells® for additional indications (including Transverse Myelitis, Multiple Sclerosis, Spinal Cord Injury, Parkinson’s, and Huntington’s), and to develop second and third generation cellular therapeutics.
Following a Howard Hughes Medical Institute postdoctoral fellowship at Stanford, Dr. Campanelli was an Assistant Professor in the Department of Biochemistry at the University of Illinois Urbana-Champaign, where his lab continued to investigate motor neuron-muscle interactions involved in the development of mature neuromuscular synapses, and then a scientist at Amersham Biosciences/GE Healthcare where he worked to develop high content assays for monocyte chemotactic and invasive behavior.
He received a B.S., M.S. and Ph.D. in biological sciences, all from Stanford University. His Ph.D. research focused on the cellular and molecular bases of neuromuscular synapse formation.
This person is not in any offices
Q Therapeutics
Q Therapeutics develops cell-based therapeutics which focuses on developing novel products to treat amyotrophic lateral sclerosis, etc.,